A high-stakes legal battle between medical scheme administrator Medscheme and Bonitas Medical Fund is set to unfold in the High Court in Johannesburg next month, intensifying scrutiny over procurement practices at one of South Africa’s largest open medical schemes. Medscheme has filed an urgent application seeking to suspend or halt certain requests for proposals issued by Bonitas in July 2025, arguing that ethical, contractual and statutory obligations to members may have been compromised.
The dispute arises against the backdrop of a regulatory process already under way. The Registrar of the Council for Medical Schemes initiated a Section 43 inquiry in February 2025 following allegations of governance failures and procurement irregularities involving senior Bonitas executives and trustees. The Council later indicated that preliminary findings warranted a full forensic investigation, although no final outcome has yet been published.
Medscheme, a subsidiary of JSE-listed AfroCentric and administrator to 14 medical schemes covering more than four million beneficiaries, contends that implementing new contracts before the forensic process is concluded could create irreversible operational and financial consequences for Bonitas members. The administrator has asked the court to interdict Bonitas from finalising or implementing awards related to administration and managed care services until regulatory processes are complete.
READ – Bonitas Ends Medscheme Partnership after Four Decades
Bonitas, however, announced in January that it had concluded the relevant tenders, awarding administration services to Momentum and managed care services to Private Health Administrators. The scheme maintains that the contested tenders are unrelated to earlier processes under investigation and argues that Medscheme’s application lacks urgency and legal basis.
The case carries broader implications for South Africa’s R250 billion private healthcare funding sector. According to data from the Council for Medical Schemes, open medical schemes face rising cost pressures, stricter governance oversight and heightened member sensitivity to service disruptions. Administrator contracts, often worth hundreds of millions of rand annually, are central to scheme stability and member experience.
With Medscheme’s current service agreement due to expire at the end of May 2026, the timing of the court hearing adds further complexity. The High Court’s decision could shape not only the immediate contractual landscape but also set a precedent for how procurement disputes within regulated healthcare entities are handled amid concurrent forensic investigations.